公开(公告)号：US10513545B2

公开(公告)日：2019-12-24

申请号：US15757580

申请日：2016-09-02

Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Jong-Sup Bae ,  In-San Kim ,  Won Hwa Lee ,  Jun Young Seo ,  So Youn Kim

IPC: C07K14/47 ,  A61K38/16 ,  A61K38/17 ,  C07K14/54 ,  C07K14/79 ,  C07K19/00 ,  A61K47/64 ,  A61P29/00 ,  C12N15/62 ,  A61K38/20 ,  A61K38/40

Abstract: The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases. As in the above, the fusion polypeptide, which has an amino acid sequence represented by SEQ ID NO: 1 and in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a fragment of a human-derived ferritin monomer, can fuse two types of anti-inflammatory polypeptides, acting through different mechanisms, into a nano cage and administer the same, and thus the fusion polypeptide can exhibit an excellent effect in the treatment of inflammatory diseases including sepsis.

公开(公告)号：US20190328721A1

公开(公告)日：2019-10-31

申请号：US16394223

申请日：2019-04-25

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： GiHoon NAM ,  Yoo Soo Yang ,  In-San Kim ,  Seung-Yoon Park

IPC: A61K31/4409 ,  A61P35/00 ,  A61P37/04 ,  A61K39/395

Abstract: Described are methods for activating dendritic cells using a Rho-related protein kinase (ROCK) inhibitor, optionally in combination with one or more of an immunogenic cell death-inducing chemotherapeutic, photodynamic therapy, or radiation therapy. The methods and treated cells are useful, for example, in treating cancer, optionally in combination with one or more of an immunogenic cell death-inducing chemotherapeutic, immune checkpoint inhibitor, photodynamic therapy, or radiation therapy.

公开(公告)号：US20240360457A1

公开(公告)日：2024-10-31

申请号：US18765587

申请日：2024-07-08

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the cancer cell via endocytosis.

公开(公告)号：US20240150771A1

公开(公告)日：2024-05-09

申请号：US18407815

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

公开(公告)号：US11246939B2

公开(公告)日：2022-02-15

申请号：US16573351

申请日：2019-09-17

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Sun Hwa Kim ,  Ick Chan Kwon ,  In-San Kim ,  Kwangmeyung Kim ,  Yoosoo Yang ,  Young-Ji Ko

IPC: A61K47/55 ,  A61K47/54 ,  A61K31/713 ,  C12N15/113 ,  C07K14/705 ,  A61P35/00 ,  A61K38/00

Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.